Edina Komlodi-Pasztor, Marta Escarra-Senmarti, Danielle A Bazer, Aastha Bhatnagar, Carlos A Perez Heydrich, Marcus Messmer, Richard F Ambinder, Douglas E Gladstone, Laura Clayton, Amy Goodrich, Laura Schoch, Nina Wagner-Johnston, Christopher J VandenBussche, Peng Huang, Matthias Holdhoff, Maximillian Rosario
The monoclonal antibody rituximab improves clinical outcome in the treatment of CD20-positive lymphomatous neoplasms, and it is an established drug for treatment of these cancers. Successful mRNA COVID-19 (SARS-CoV-2) vaccination is extremely important for lymphoma patients because they tend to be elderly with comorbidities which leaves them at increased risk of poor outcomes once infected by Coronavirus. Anti-CD20 therapies such as rituximab, deplete B-cell populations and can affect vaccine efficacy. Therefore, a knowledge of the effect of COVID-19 vaccination in this group is critical...
2024: Frontiers in Immunology